Insider · CIK 0002049407
Shulamit Ron-Bigger
Files at AKTS (Aktis Oncology, Inc.). First filing Jul 10, 2026, latest Jul 10, 2026.
In brief
Shulamit Ron-Bigger files SEC Form 4 as COO at AKTS (Aktis Oncology, Inc.). Since Jul 10, 2026, Shulamit Ron-Bigger has reported 0 open-market buys worth $0 and 1 open-market sell worth $1.4M, the latest filed on Jul 10, 2026.
A track record needs three past buys with six months of prices behind them; Shulamit Ron-Bigger has 0, so none is measured yet.
The newest scored trade: sold $1.4M of AKTS on Jul 8, 2026, filed Jul 10, 2026, scored 65 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $1.4M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | Aktis Oncology, Inc. | $1.4M 50,000 shares | -100% | +89% from low-11% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 8, 2026 | AKTS AKTIS ONCOLOGY, INC. | 50,000 0.09% of outstanding | $1.4M | Jul 8, 2026 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Common Stock | +50,000 | $3.66 | $183k | 50,000 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -15,800 | $27.13 | $429k | 34,200 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -30,000 | $27.94 | $838k | 4,200 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | SOpen-market sale Common Stock | -4,200 | $28.75 | $121k | 0 | Jul 10, 2026 |
| Jul 8, 2026 | AKTS Aktis Oncology, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 217,888 | Jul 10, 2026 |
Questions about Shulamit Ron-Bigger
Answered from the filings on this page, as of the latest one.
Is Shulamit Ron-Bigger buying or selling?
In the last 12 months Shulamit Ron-Bigger reported 0 open-market buys worth $0 and 1 open-market sell worth $1.4M on SEC Form 4; the latest was sold $1.4M of AKTS on Jul 8, 2026. Grants, option exercises and tax withholding are not counted.
How did Shulamit Ron-Bigger's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Shulamit Ron-Bigger has 0.
Where does Shulamit Ron-Bigger file Form 4?
Shulamit Ron-Bigger has filed Form 4 at AKTS (Aktis Oncology, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.